Terms: = Breast cancer AND PBRM1, BAF180, 55193, PB1, MGC156156, MGC156155
22 results:
1. Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma.
Yang X; Lian B; Zhang N; Long J; Li Y; Xue J; Chen X; Wang Y; Wang Y; Xun Z; Piao M; Zhu C; Wang S; Sun H; Song Z; Lu L; Dong X; Wang A; Liu W; Pan J; Hou X; Guan M; Huo L; Shi J; Zhang H; Zhou J; Lu Z; Mao Y; Sang X; Wu L; Yang X; Wang K; Zhao H
BMC Med; 2024 Jan; 22(1):42. PubMed ID: 38281914
[TBL] [Abstract] [Full Text] [Related]
2. Impact of Mutations in Subunit Genes of the Mammalian SWI/SNF Complex on Immunological Tumor Microenvironment.
Hozumi C; Iizuka A; Ikeya T; Miyata H; Maeda C; Ashizawa T; Nagashima T; Urakami K; Shimoda Y; Ohshima K; Muramatsu K; Sugino T; Shiomi A; Ohde Y; Bando E; Furukawa K; Sugiura T; Mukaigawa T; Nishimura S; Hirashima Y; Mitsuya K; Yoshikawa S; Tsubosa Y; Katagiri H; Niwakawa M; Yamaguchi K; Kenmotsu H; Akiyama Y
Cancer Genomics Proteomics; 2024; 21(1):88-101. PubMed ID: 38151294
[TBL] [Abstract] [Full Text] [Related]
3. In vivo CRISPR/Cas9 screening identifies pbrm1 as a regulator of myeloid leukemia development in mice.
Li BE; Li GY; Cai W; Zhu Q; Seruggia D; Fujiwara Y; Vakoc CR; Orkin SH
Blood Adv; 2023 Sep; 7(18):5281-5293. PubMed ID: 37428871
[TBL] [Abstract] [Full Text] [Related]
4. MUC1-C Dictates pbrm1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative breast cancer.
Yamashita N; Morimoto Y; Fushimi A; Ahmad R; Bhattacharya A; Daimon T; Haratake N; Inoue Y; Ishikawa S; Yamamoto M; Hata T; Akiyoshi S; Hu Q; Liu T; Withers H; Liu S; Shapiro GI; Yoshizumi T; Long MD; Kufe D
Mol Cancer Res; 2023 Mar; 21(3):274-289. PubMed ID: 36445328
[TBL] [Abstract] [Full Text] [Related]
5. Genomic alteration profile and PD-L1 expression among different breast cancer subtypes in Chinese population and their correlations.
Li K; Cao L; Li C; Wu J; Chen B; Zhang G; Li X; Wen L; Jia M; Wei G; Lin J; Li Y; Zhang Y; Mok H; Ren C; Wang Y; Qi X; Guo L; Che Y; Liao N
Cancer Med; 2023 Mar; 12(5):5195-5208. PubMed ID: 36404592
[TBL] [Abstract] [Full Text] [Related]
6. pbrm1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in cancer.
Chabanon RM; Morel D; Eychenne T; Colmet-Daage L; Bajrami I; Dorvault N; Garrido M; Meisenberg C; Lamb A; Ngo C; Hopkins SR; Roumeliotis TI; Jouny S; Hénon C; Kawai-Kawachi A; Astier C; Konde A; Del Nery E; Massard C; Pettitt SJ; Margueron R; Choudhary JS; Almouzni G; Soria JC; Deutsch E; Downs JA; Lord CJ; Postel-Vinay S
Cancer Res; 2021 Jun; 81(11):2888-2902. PubMed ID: 33888468
[TBL] [Abstract] [Full Text] [Related]
7. Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma.
Bi K; He MX; Bakouny Z; Kanodia A; Napolitano S; Wu J; Grimaldi G; Braun DA; Cuoco MS; Mayorga A; DelloStritto L; Bouchard G; Steinharter J; Tewari AK; Vokes NI; Shannon E; Sun M; Park J; Chang SL; McGregor BA; Haq R; Denize T; Signoretti S; Guerriero JL; Vigneau S; Rozenblatt-Rosen O; Rotem A; Regev A; Choueiri TK; Van Allen EM
Cancer Cell; 2021 May; 39(5):649-661.e5. PubMed ID: 33711272
[TBL] [Abstract] [Full Text] [Related]
8. Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic breast cancer.
Sivapiragasam A; Ashok Kumar P; Sokol ES; Albacker LA; Killian JK; Ramkissoon SH; Huang RSP; Severson EA; Brown CA; Danziger N; McGregor K; Ross JS
Cancer Med; 2021 Jan; 10(1):53-61. PubMed ID: 33314633
[TBL] [Abstract] [Full Text] [Related]
9. Targeted next-generation sequencing assays using triplet samples of normal breast tissue, primary breast cancer, and recurrent/metastatic lesions.
Akahane T; Kanomata N; Harada O; Yamashita T; Kurebayashi J; Tanimoto A; Moriya T
BMC Cancer; 2020 Oct; 20(1):944. PubMed ID: 33004031
[TBL] [Abstract] [Full Text] [Related]
10. miR526b and miR655 Induce Oxidative Stress in breast cancer.
Shin B; Feser R; Nault B; Hunter S; Maiti S; Ugwuagbo KC; Majumder M
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31430859
[TBL] [Abstract] [Full Text] [Related]
11. Design of a Targeted Sequencing Assay to Detect Rare Mutations in Circulating Tumor DNA.
Chen J; Chen J; He F; Huang Y; Lu S; Fan H; Wang M; Xu R
Genet Test Mol Biomarkers; 2019 Apr; 23(4):264-269. PubMed ID: 30986100
[TBL] [Abstract] [Full Text] [Related]
12. Mapping Bromodomains in breast cancer and association with clinical outcome.
Pérez-Pena J; Páez R; Nieto-Jiménez C; Sánchez VC; Galan-Moya EM; Pandiella A; Győrffy B; Ocana A
Sci Rep; 2019 Apr; 9(1):5734. PubMed ID: 30952871
[TBL] [Abstract] [Full Text] [Related]
13. Focusing on the Influenza Virus Polymerase Complex: Recent Progress in Drug Discovery and Assay Development.
Zhang J; Hu Y; Musharrafieh R; Yin H; Wang J
Curr Med Chem; 2019; 26(13):2243-2263. PubMed ID: 29984646
[TBL] [Abstract] [Full Text] [Related]
14. The cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.
Ricketts CJ; De Cubas AA; Fan H; Smith CC; Lang M; Reznik E; Bowlby R; Gibb EA; Akbani R; Beroukhim R; Bottaro DP; Choueiri TK; Gibbs RA; Godwin AK; Haake S; Hakimi AA; Henske EP; Hsieh JJ; Ho TH; Kanchi RS; Krishnan B; Kwiatkowski DJ; Liu W; Merino MJ; Mills GB; Myers J; Nickerson ML; Reuter VE; Schmidt LS; Shelley CS; Shen H; Shuch B; Signoretti S; Srinivasan R; Tamboli P; Thomas G; Vincent BG; Vocke CD; Wheeler DA; Yang L; Kim WY; Robertson AG; ; Spellman PT; Rathmell WK; Linehan WM
Cell Rep; 2018 Apr; 23(1):313-326.e5. PubMed ID: 29617669
[TBL] [Abstract] [Full Text] [Related]
15. baf180: Its Roles in DNA Repair and Consequences in cancer.
Hopson S; Thompson MJ
ACS Chem Biol; 2017 Oct; 12(10):2482-2490. PubMed ID: 28921948
[TBL] [Abstract] [Full Text] [Related]
16. High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma.
Yoshikawa Y; Emi M; Hashimoto-Tamaoki T; Ohmuraya M; Sato A; Tsujimura T; Hasegawa S; Nakano T; Nasu M; Pastorino S; Szymiczek A; Bononi A; Tanji M; Pagano I; Gaudino G; Napolitano A; Goparaju C; Pass HI; Yang H; Carbone M
Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13432-13437. PubMed ID: 27834213
[TBL] [Abstract] [Full Text] [Related]
17. Low pbrm1 identifies tumor progression and poor prognosis in breast cancer.
Mo D; Li C; Liang J; Shi Q; Su N; Luo S; Zeng T; Li X
Int J Clin Exp Pathol; 2015; 8(8):9307-13. PubMed ID: 26464681
[TBL] [Abstract] [Full Text] [Related]
18. Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival.
Mathiesen RR; Borgen E; Renolen A; Løkkevik E; Nesland JM; Anker G; Ostenstad B; Lundgren S; Risberg T; Mjaaland I; Kvalheim G; Lønning PE; Naume B
Breast Cancer Res; 2012 Aug; 14(4):R117. PubMed ID: 22889108
[TBL] [Abstract] [Full Text] [Related]
19. Polybromo-1: the chromatin targeting subunit of the PBAF complex.
Thompson M
Biochimie; 2009 Mar; 91(3):309-19. PubMed ID: 19084573
[TBL] [Abstract] [Full Text] [Related]
20. baf180 is a critical regulator of p21 induction and a tumor suppressor mutated in breast cancer.
Xia W; Nagase S; Montia AG; Kalachikov SM; Keniry M; Su T; Memeo L; Hibshoosh H; Parsons R
Cancer Res; 2008 Mar; 68(6):1667-74. PubMed ID: 18339845
[TBL] [Abstract] [Full Text] [Related]
[Next]
